Thermo Fisher Scientific Launches Gibco™ VaxEvo™ CD 293 Medium
Thermo Fisher Scientific has introduced the Gibco™ VaxEvo™ CD 293 Medium, a chemically defined, animal origin-free medium designed to support adenovirus vaccine production.
Stocks · News reference
Thermo Fisher Scientific declared a quarterly cash dividend of $0.47 per common share.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Thermo Fisher Scientific has introduced the Gibco™ VaxEvo™ CD 293 Medium, a chemically defined, animal origin-free medium designed to support adenovirus vaccine production.
CAPE EMS Berhad, through its subsidiary iConn Technologies, has finalized a multi-year contract manufacturing agreement with Thermo Fisher Scientific to support its life sciences operations.
Thermo Fisher Scientific announced that Chairman and CEO Marc N. Casper will participate in a fireside chat hosted by UBS on November 19, 2026.
The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.
The global nucleic acid labeling market is projected to grow from $1.7 billion in 2025 to $2.8 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in genomics, molecular diagnostics, NGS, and high-throughput laboratory workflows. Key applications include oligonucleotide labeling and in-situ hybridization, with the U.S. and China representing major regional markets.
Thermo Fisher Scientific has completed multiple installations of its Optis™ focused ion beam-scanning electron microscope (FIB-SEM) to support semiconductor manufacturers in developing complex chips.